On July 23–24, 2026, an FDA advisory committee reviews seven peptides. A lot of the internet is treating that date like a finish line. It's a starting line, and the difference matters before you trust anyone selling these today.
The Pharmacy Compounding Advisory Committee (PCAC) is a federal advisory committee. It reviews substances and makes recommendations, and those recommendations are non-binding. The FDA decides what to do with them.
| July 23, 2026 | July 24, 2026 |
|---|---|
| BPC-157 · KPV · TB-500 · MOTS-c | Emideltide (DSIP) · Semax · Epitalon |
Category 1 means a substance can be compounded under interim policy with clinical oversight. It does not mean the substance went through FDA drug approval. Compounded medications are not FDA-evaluated for safety, efficacy, or quality.
Two different things are both called a "list," and conflating them is the most common error here. The 503A Bulks List is notice-and-comment rulemaking codified at 21 CFR 216.23 and contains six substances — Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. None of them is a peptide. Interim Category 1 is a website document covering roughly 48 substances under enforcement discretion only. FDA has also said it does not intend to place bulk drug substances nominated on or after January 7, 2025 into these categories, so the interim framework is being wound down. Sites claiming these peptides are "Category 1 now" or "available after July" are wrong, and that's exactly the kind of claim our FDA Tracker exists to neutralize. Reclassification is not the same as FDA approval, and a PCAC recommendation is not availability.